ArticleJournal of translational medicine2026
Tissue nonspecific and intestinal alkaline phosphatase crosstalk: a missing link in hypophosphatasia pathophysiology?
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTissue-nonspecific alkaline phosphatase (TNSALP) and intestinal alkaline phosphatase (IAP) are functionally similar enzymes, but their relationship in hypophosphatasia (HPP) remains unexplored. This study investigated the impact of HPP-a condition caused by ALPL gene mutations that impair TNSALP function-on serum and fecal IAP activity.
methodsTotal alkaline phosphatase (ALP) activity and isoenzyme-specific activities (using selective inhibitors: L-homoarginine for TNSALP, L-phenylalanine for IAP) were measured in serum and stool samples from 30 HPP patients and 30 matched healthy controls, alongside biochemical parameters correlations.
resultsIn serum, IAP activity showed a non-significant decrease in HPP patients compared to controls, while TNSALP and total ALP activity were reduced in HPP patients. In stools, both total ALP and IAP activities were significantly decreased compared to the control group. Multivariate linear regression revealed a strong positive association between TNSALP and IAP in both serum and feces, independent of age and sex. In serum, TNSALP and IAP were key predictors of total ALP activity (B = 0.876 and B = 0.745, respectively; p < 0.001; R² = 0.9396), with TNSALP also predicting serum IAP levels (B = 0.164; p < 0.001). In feces, IAP was the strongest predictor of total ALP activity (B = 0.921; p < 0.001), and fecal TNSALP strongly predicted IAP levels (B = 0.883; p < 0.001). Serum TNSALP activity correlated with bone metabolism markers, inflammation, underscoring its potential systemic role.
conclusionsIAP does not seem to compensate for reduced TNSALP activity in HPP. Instead, their tight association suggests a coordinated regulation between the two isoenzymes, with diminished fecal IAP potentially contributing to gut inflammation in HPP. These findings clarify the interplay between TNSALP and IAP and their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.